retatrutide triple agonist glp-1 gip glucagon phase 2 trial obesity just had its biggest data year yet. In 2026, Eli Lilly's GLP-1/GIP/glucagon receptor posted two major 3 readouts: TRIUMPH-1 (obesity, 2,339 participants) showed a 28.3% average body weight From Obesity to Metabolic Health:

Recent Developments: Continued expansion of Wegovy's indications, including applications for cardiovascular risk reduction

It is produced in the intestine in response to food intake, so, like, when you eat, it is produced

However, inform both your weight loss provider and anticoagulation doctor of the combination

Even small changes in metabolism, nutrition, or medication absorption can alter how effectively the therapy works

Inside interoception: The hidden sense of how you feel inside Researchers are decoding how signals move between body and brain, with implications for how we understand and treat conditions from obesity to anxiety

Glucagon-like peptide-1 receptor agonists associated gastrointestinal adverse events: a cross-sectional analysis of the national institutes of health all of us cohort